Abstract:Enteric fever is caused by the infection of Gram-negative bacteria, Salmonella enterica serovar Typhi and Salmonella enterica serovar Paratyphi (S. Paratyphi) A, B and C, through contaminated food and water. The disease almost exclusively affects the populations living in low- and middle-income countries, with the World Health Organization Southeast Asian Region (WHO SEAR) having the highest endemicity. Despite humans being the sole reservoir of infection and antibiotics and vaccines are made available, the disease was not taken up for elimination until recently due to several biological and technical reasons, including the lack of accurate and region-specific disease surveillance data in the real-time diagnostic inaccuracy of acute infections, difficulty in identifying the chronic asymptomatic carriers who are the major reservoirs of infection and the absence of a political will. However, there is now a renewed interest and effort to control the disease in the endemic areas with the help of better surveillance tools to monitor disease burden, wider availability of more accurate blood culture methods for diagnosis, and above all, cost-effective typhoid conjugate vaccines (TCVs) that can provide a high level of durable protection, particularly against the multidrug-resistant strains and to the age group most commonly affected by the disease. However, despite the commercial availability of a few TCVs, they are still in the development stage. Several questions need to be answered before they are taken up for routine immunization in countries like India. Furthermore, typhoid vaccines with a wider coverage, including additional efficacy against Salmonella Paratyphi A and B and preferably the non-typhoidal Salmonella (NTS) serovars, for which no vaccines are currently available would be more desirable. We have developed several subunit vaccine candidates containing the glycoconjugates of the surface polysaccharides of typhoidal and non-typhoidal Salmonellae and an intrinsic Salmonella protein that functions as both antigen and adjuvant. We also developed a novel mouse model of oral Salmonella Typhi infection to test the candidate vaccines, which demonstrated broad protective efficacy against Salmonella spp. through the induction of humoral and cell-mediated immunity as well as memory response.

Cholera, plague, typhoid, and paratyphoid: a cautious start to a vaccine revolution

Cholera: Prevention and Vaccination

Modern History of Cholera Vaccines and the Pivotal Role of icddr,b

[Vaccination against diarrheal diseases and typhoid fever. Current status and prospects]

Vaccines Through Centuries: Major Cornerstones of Global Health

Progress towards Development of a Cholera Subunit Vaccine

Improving immunization approaches to cholera

Anti-Infectious Human Vaccination in Historical Perspective

Typhoid & paratyphoid vaccine development in the laboratory: a review & in-country experience

The state-of-the-art of approved and under-development cholera vaccines

Cholera vaccine: new preventive tool for endemic countries

A review of the current status of enteric vaccines

Emergence of a New Cholera Pandemic: Molecular Analysis of Virulence Determinants in Vibrio cholerae 0139 and Development of a Live Vaccine Prototype

The true burden and risk of cholera: implications for prevention and control

The utility of human challenge studies in vaccine development: lessons learned from cholera

Vaccines against cholera, typhoid fever and shigellosis for developing countries

Lessons from cholera & Vibrio cholerae

Cholera: Immunity and Prospects in Vaccine Development

Plague Vaccine Development: Current Research and Future Trends

Oral vaccination against enteric bacterial infections: An overview

From ancient remedies to modern miracles: tracing the evolution of vaccines and their impact on public health